You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!
Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Revance Therapeutics
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001)...
Seeking AlphaFeb 26
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q4 2018 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Daniel Browne - President and Chief Executive Officer Tobin Schilke - Chief Financial Officer Abhay Joshi - Chief Operating Officer Dustin Sjuts - Head of Commercial Aesthetics and Therapeutics Conference Call Participants Stacy Ku - Cowen and Company David Amsellem - Piper Jaffray & Co. Nicho...
Simply Wall StFeb 19
What Kind Of Shareholder Appears On The Revance Therapeutics, Inc.’s (NASDAQ:RVNC) Shareholder Register?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you want to know who really controls Revance Therapeutics, Inc. (NASDAQ:RVNC), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned. With a market capitali...
Expected May 7, After Hours